Caseware UK (AP4) 2023.0.135 2023.0.135 2024-04-302024-04-30falsefalse2023-05-01No description of principal activity22truetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 09570223 2023-05-01 2024-04-30 09570223 2022-05-01 2023-04-30 09570223 2024-04-30 09570223 2023-04-30 09570223 2022-05-01 09570223 2 2023-05-01 2024-04-30 09570223 2 2022-05-01 2023-04-30 09570223 d:Director1 2023-05-01 2024-04-30 09570223 e:OfficeEquipment 2023-05-01 2024-04-30 09570223 e:OfficeEquipment 2024-04-30 09570223 e:OfficeEquipment 2023-04-30 09570223 e:OfficeEquipment e:OwnedOrFreeholdAssets 2023-05-01 2024-04-30 09570223 e:CurrentFinancialInstruments 2024-04-30 09570223 e:CurrentFinancialInstruments 2023-04-30 09570223 e:CurrentFinancialInstruments e:WithinOneYear 2024-04-30 09570223 e:CurrentFinancialInstruments e:WithinOneYear 2023-04-30 09570223 e:ShareCapital 2023-05-01 2024-04-30 09570223 e:ShareCapital 2024-04-30 09570223 e:ShareCapital 2022-05-01 2023-04-30 09570223 e:ShareCapital 2023-04-30 09570223 e:ShareCapital 2022-05-01 09570223 e:OtherMiscellaneousReserve 2023-05-01 2024-04-30 09570223 e:OtherMiscellaneousReserve 2024-04-30 09570223 e:OtherMiscellaneousReserve 2 2023-05-01 2024-04-30 09570223 e:OtherMiscellaneousReserve 2022-05-01 2023-04-30 09570223 e:OtherMiscellaneousReserve 2023-04-30 09570223 e:OtherMiscellaneousReserve 2022-05-01 09570223 e:OtherMiscellaneousReserve 2 2022-05-01 2023-04-30 09570223 e:RetainedEarningsAccumulatedLosses 2023-05-01 2024-04-30 09570223 e:RetainedEarningsAccumulatedLosses 2024-04-30 09570223 e:RetainedEarningsAccumulatedLosses 2 2023-05-01 2024-04-30 09570223 e:RetainedEarningsAccumulatedLosses 2022-05-01 2023-04-30 09570223 e:RetainedEarningsAccumulatedLosses 2023-04-30 09570223 e:RetainedEarningsAccumulatedLosses 2022-05-01 09570223 e:RetainedEarningsAccumulatedLosses 2 2022-05-01 2023-04-30 09570223 d:FRS102 2023-05-01 2024-04-30 09570223 d:AuditExempt-NoAccountantsReport 2023-05-01 2024-04-30 09570223 d:FullAccounts 2023-05-01 2024-04-30 09570223 d:PrivateLimitedCompanyLtd 2023-05-01 2024-04-30 09570223 2 2023-05-01 2024-04-30 09570223 6 2023-05-01 2024-04-30 09570223 f:PoundSterling 2023-05-01 2024-04-30 iso4217:GBP xbrli:pure
Registered number: 09570223


ALMEIDA RIBAU MEDICAL LTD
UNAUDITED
FINANCIAL STATEMENTS
INFORMATION FOR FILING WITH THE REGISTRAR
FOR THE YEAR ENDED 30 APRIL 2024

 
ALMEIDA RIBAU MEDICAL LTD
REGISTERED NUMBER:09570223

BALANCE SHEET
AS AT 30 APRIL 2024

2024
2023
Note
£
£

Fixed assets
  

Tangible assets
 5 
14,446
14,583

Investments
 6 
1,142,947
773,806

  
1,157,393
788,389

Current assets
  

Debtors: amounts falling due within one year
 7 
25,938
13,034

Cash at bank and in hand
  
40,516
35,736

  
66,454
48,770

Creditors: amounts falling due within one year
 8 
(32,228)
(25,901)

Net current assets
  
 
 
34,226
 
 
22,869

Total assets less current liabilities
  
1,191,619
811,258

Provisions for liabilities
  

Deferred tax
  
(140,833)
(46,030)

  
 
 
(140,833)
 
 
(46,030)

Net assets
  
1,050,786
765,228


Capital and reserves
  

Called up share capital 
  
100
100

Other reserves
  
411,663
184,419

Profit and loss account
  
639,023
580,709

  
1,050,786
765,228


Page 1

 
ALMEIDA RIBAU MEDICAL LTD
REGISTERED NUMBER:09570223
    
BALANCE SHEET (CONTINUED)
AS AT 30 APRIL 2024

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




Goncalo Alexandre Da Costa Almeida
Director

Date: 22 January 2025

The notes on pages 4 to 9 form part of these financial statements.

Page 2

 
ALMEIDA RIBAU MEDICAL LTD
 

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 APRIL 2024


Called up share capital
Fair value reserve
Profit and loss account
Total equity

£
£
£
£


At 1 May 2022
100
155,821
513,008
668,929


Comprehensive income for the year

Profit for the year
-
-
122,549
122,549
Total comprehensive income for the year
-
-
122,549
122,549


Contributions by and distributions to owners

Dividends: Equity capital
-
-
(26,250)
(26,250)

Fair value movements
-
28,598
(28,598)
-


Total transactions with owners
-
28,598
(54,848)
(26,250)



At 1 May 2023
100
184,419
580,709
765,228


Comprehensive income for the year

Profit for the year
-
-
315,308
315,308
Total comprehensive income for the year
-
-
315,308
315,308


Contributions by and distributions to owners

Dividends: Equity capital
-
-
(29,750)
(29,750)

Fair value movements
-
227,244
(227,244)
-


Total transactions with owners
-
227,244
(256,994)
(29,750)


At 30 April 2024
100
411,663
639,023
1,050,786


The notes on pages 4 to 9 form part of these financial statements.

Page 3

 
ALMEIDA RIBAU MEDICAL LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

1.


General information

Almeida Ribau Medical Limited is a company limited by shares incorporated in England, United Kingdom. The address of the registered office is Victoria Court, 17-21 Ashford Road, Maidstone, Kent, ME14 5DA.
The financial statements are presented in sterling which is the functional currency of the company and rounded to the nearest £1.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgement in applying the Company's accounting policies (see note 3).

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.3

Interest income

Interest income is recognised in profit or loss using the effective interest method.

Page 4

 
ALMEIDA RIBAU MEDICAL LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

2.Accounting policies (continued)

 
2.4

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


 
2.5

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, on a reducing balance basis.

Depreciation is provided on the following basis:

Office equipment
-
25%

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

Page 5

 
ALMEIDA RIBAU MEDICAL LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

2.Accounting policies (continued)

 
2.6

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

Investments in unlisted Company shares, whose market value can be reliably determined, are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in the Statement of Comprehensive Income for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment.

Investments in listed company shares are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in profit or loss for the period.

 
2.7

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.8

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.9

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.10

Provisions for liabilities

Provisions are recognised when an event has taken place that gives rise to a legal or constructive obligation, a transfer of economic benefits is probable and a reliable estimate can be made.
Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties.
 
Increases in provisions are generally charged as an expense to profit or loss.

 
2.11

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Judgements in applying accounting policies and key sources of estimation uncertainty

No significant judgements have been made by management in preparing these financial statements.

Page 6

 
ALMEIDA RIBAU MEDICAL LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

4.


Employees

The average monthly number of employees, including directors, during the year was 2 (2023 - 2).

Page 7

 
ALMEIDA RIBAU MEDICAL LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

5.


Tangible fixed assets





Office equipment

£



Cost or valuation


At 1 May 2023
29,082


Additions
4,678



At 30 April 2024

33,760



Depreciation


At 1 May 2023
14,499


Charge for the year on owned assets
4,815



At 30 April 2024

19,314



Net book value



At 30 April 2024
14,446



At 30 April 2023
14,583


6.


Fixed asset investments





Listed investments

£



Cost or valuation


At 1 May 2023
773,806


Additions
47,845


Revaluations
321,296



At 30 April 2024
1,142,947




Page 8

 
ALMEIDA RIBAU MEDICAL LTD
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

7.


Debtors

2024
2023
£
£


Trade debtors
19,115
12,464

Other debtors
6,275
-

Prepayments and accrued income
548
570

25,938
13,034



8.


Creditors: Amounts falling due within one year

2024
2023
£
£

Trade creditors
850
850

Other creditors
27,378
20,519

Accruals and deferred income
4,000
4,532

32,228
25,901


 
Page 9